Core Viewpoint - Micron Heart Technology-B (02160) saw a significant increase of over 6%, currently trading at 0.84 HKD with a transaction volume of 8.5992 million HKD, following the announcement of its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN entering the special review process by the National Medical Products Administration (NMPA) [1] Group 1 - The NMPA's Medical Device Technology Review Center has published the review results for the special application of innovative medical devices, indicating a potential approval for the TILEN/EYLEN ICD [1] - TILEN/EYLEN is expected to be the first domestically approved ICD with independent intellectual property rights that is safe for use under magnetic resonance conditions [1]